I have eco-anxiety but that's normal

Publication date: 12 October 2019Source: New Scientist, Volume 244, Issue 3251Author(s): Graham LawtonThe UK media reports widespread eco-anxiety in kids. If we accept it is a mental health condition, climate denialists will have won, writes Graham Lawton
Source: New Scientist - Category: Science Source Type: research

Related Links:

BACKGROUND: Improving the rates of, and instruments used in, screening for perinatal depression and anxiety among Aboriginal and Torres Strait Islander women are important public health priorities. The Kimberley Mum's Mood Scale (KMMS) was developed and la...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news
Intimate partner violence (IPV) among married women of childbearing age can significantly enhance their risk of adverse health outcomes such as injury and disability, depression and anxiety, unwanted pregnancies, premature labor, complications with deliver...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
CONCLUSION: The Turkish version of the Neck Bournemouth Questionnaire is valid and reliable. Key Words: Health related quality of life, disability, chronic neck pain. PMID: 31731331 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
Chronic back pain (CBP) is a major global health problem, while its treatment is hampered by a lack of efficacy and restricted safety profile of common frontline therapies. The present trial aims to determine whether a 3-week open-label placebo treatment reduces pain intensity and subjective and objective functional disability in patients with CBP. This randomized controlled trial, following a pretest–posttest design, enrolled 127 patients with CBP (pain duration>12 weeks) from the Back Pain Center, Neurology, University Hospital Essen, Germany. Patients randomized to the open-label placebo group received a 3-week...
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
BACKGROUND: Rates of anxiety and depression are increasing among children and young people. Recent policies have focused on primary prevention of mental disorders in children and young people, with schools at the forefront of implementation. There is limit...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Depression and anxiety are common neuropsychiatric manifestations of Parkinson disease. However, they are often under-recognized because the somatic symptoms of depression often overlap with the motor symptoms of Parkinson disease and there is low self-rep...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
ConclusionsU.S. children and adolescents are prescribed benzodiazepines for various mental health and other medical conditions, many lacking evidence of pediatric efficacy. Long-term benzodiazepine treatment, concurrent opioid prescriptions, psychotropic use, and prior substance use disorder diagnoses suggest safety risks among some youth prescribed benzodiazepines.
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Publication date: January 2020Source: Epilepsy &Behavior, Volume 102Author(s): Maria Anesti, Natalia Stavropoulou, Korina Atsopardi, Fotini N. Lamari, Nikolaos T. Panagopoulos, Marigoula MargarityAbstractThe aim of the present study was to investigate the effect of rutin administration (100 mg/kg/day) to pentylenetetrazol (PTZ)-treated Balb-c mice (60 mg/kg/day), with respect to anxiety-like behavior using both open-field and elevated plus-maze (EPM) tests, and acetylcholinesterase (AChE) activity in salt-soluble (SS) fraction and detergent-soluble (DS) fraction of the cerebral cortex, hippocampus, striatum, midbra...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
Source: Anxiety, Stress and Coping - Category: Psychiatry & Psychology Authors: Source Type: research
We studied the effect of gonadotropin-releasing hormone agonist surfagon (2 μg/kg, once, intraperitoneally) on anxious behavior of adult gonadectomized and non-gonadectomized male rats. It was shown that surfagon significantly increased anxiety of both gonadectomized and non-gonadectomized rats in the open-field test and in elevated plus maze
Source: Bulletin of Experimental Biology and Medicine - Category: Biology Source Type: research
More News: Anxiety | Children | Legislation | Men | Science